RCS - Oxford Cannabinoid - Inaugural Meeting of Scientific Advisory Board

Oxford Cannabinoid Technologies HoldingsAnnouncement

15/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220815:nRSO9877Va&default-theme=true

RNS Number : 9877V  Oxford Cannabinoid Tech.Holdings  15 August 2022

15 August 2022

 

Oxford Cannabinoid Technologies Holdings plc

("OCTP", or the "Company")

Inaugural Meeting of Scientific Advisory Board

 

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the
pharmaceutical company developing prescription cannabinoid medicines targeting
the US$ multi-billion pain market is pleased to announce that the Company
recently held its inaugural Scientific Advisory Board ("SAB") meeting in
London, hosted by Dr. Valentino Parravicini, OCTP's Chief Scientific Officer.

 

Dr. Parravicini was joined by Professor Anthony Dickenson (University College
London), Dr. Giorgio Lambru (Guy's and St Thomas' NHS Foundation Trust,
London), and Professor Robert Dworkin (Rochester Medica Center School of
Medicine and Dentistry, New York).

 

As announced in April
(https://www.londonstockexchange.com/news-article/OCTP/formation-of-scientific-advisory-board/15422530)
, with the Company's current focus on the treatment of neuropathic pain
conditions, and its progress towards clinical trials, the SAB's topics for
discussion focussed on linking pre-clinical research, clinical trials and the
care of patients. The SAB also provided advice and guidance on the design of
the Company's upcoming Phase 1 clinical trials for OCT130401 and OCT461201,
anticipated in Q4 2022 and Q1 2023 respectively, to help OCTP best address the
needs of patients.

 

It is anticipated that the SAB will meet on a quarterly basis, with the next
session planned for early December 2022.

 

OCTP Chief Scientific Officer, Dr. Valentino Parravicini commented:

 

"It is a great privilege to benefit from the vast experience of Professors
Dworkin and Dickenson and Dr. Lambru. The meeting was very engaging,
generating new, innovative proposals to strengthen the Group's clinical
strategy which I am looking forward to putting into action."

The directors take responsibility for this announcement.

Enquiries:

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Dr John Lucas (CEO)                            john@oxcantech.com

 Clarissa Sowemimo-Coker (COO)                 clarissa@oxcantech.com

 Walbrook PR Limited                           +44 (0)20 7933 8780

 Paul Vann/Nick Rome/Joe Walker                +44 (0)7768 807631

                                               oxcantech@walbrookpr.com

 Harbor Access LLC (US/OTCB enquiries)

 Jonathan Paterson                             +1 (203) 862 0492

 Richard Leighton                              Richard.Leighton@harboraccessllc.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company
of Oxford Cannabinoid Technologies Ltd ("OCT") (together the "Group"), a
pharmaceutical Group developing prescription cannabinoid medicines for
approval by key medicines regulatory agencies worldwide and targeting the U$
multi-billion pain market. Cannabinoids are compounds found in the cannabis
plant that have been shown to have a range of therapeutic effects on the body,
including pain relief. The Group has a clearly defined path to
commercialisation, revenues and growth. The Group is developing drug
candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA)
that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst
ensuring market exclusivity around all its key activities. The Group's lead
compound, OCT461201, is a highly potent and selective CB2 agonist and is being
developed by OCT in a solid oral dosage form. OCTP is conducting pre-clinical
testing and development with clinical trials scheduled for Q1 2023. The
Group's product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of rare
diseases and includes chemically modified phytocannabinoids with improved
drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial
partners.

About the SAB

Professor Robert Dworkin, who has been a consultant to the Company since
November 2021, is a Professor in the departments of Anesthesiology and
Perioperative Medicine, Neurology, and Psychiatry at the University of
Rochester Medical Center School of Medicine and Dentistry, New York State. He
is also a Director of ACTTION (Analgesic, Anesthetic, and Addiction Clinical
Trial Translations, Innovations, Opportunities, and Networks) a public-private
partnership with the United States Food and Drug Administration. Professor
Dworkin's major research interests are the methodologic aspects of analgesic
clinical trials and the treatment and prevention of chronic neuropathic and
musculoskeletal pain. Through ongoing studies he is evaluating the research
designs and methods, clinical outcome assessments, and statistical analyses
used in clinical trials of treatments for acute and chronic pain.

 

Doctor Giorgio Lambru, who has been a consultant to the Company since February
2022, is a Consultant Neurologist at Guy's & St Thomas' NHS Foundation
Trust, London, and Honorary Senior Lecturer at King's College London. Dr
Lambru is an expert in headache and facial pain conditions, including
neuropathic pain and general neurology conditions. He has authored a number of
scientific publications on these conditions and has a clinic dedicated to
complex headache and facial pain disorders.

Professor Anthony Dickenson, who has been a consultant to the Company since
May 2021, is Emeritus Professor of Neuropharmacology at University College,
London. Professor Dickenson's research is focused on understanding the
mechanisms of pain including how pain can be controlled in both normal and
patho-physiological conditions and how to translate basic science to patients.
He is an Honorary Member of the British Pain Society, a member of the council
of the International Association for the Study of Pain, was a founding member
of the London Pain Consortium (Welcome Trust), and is involved in many
advisory boards.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFIFLETSIELIF